News
Eli Lilly’s Zepbound proved more effective than Novo Nordisk’s Wegovy in a new head-to-head trial, though both medications ...
For a limited time, Wegovy will be available to new patients at $199 for the first month, Novo Nordisk said Thursday.
The results of the first head-to-head trial of Lilly's dual GLP-1/GIP agonist Zepbound (tirzepatide) and Novo Nordisk's GLP-1 agonist Wegovy (semaglutide) have shown experimentally what has been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results